Avidity Biosciences Reports Second Quarter 2020 Financial Results and Recent Highlights

SAN DIEGO, Aug. 10, 2020 /PRNewswire/ — Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the quarter and six months ended…


Read More